RESUMO
A new ternary complex hydride is synthesized by the interaction between Li2NH and LiBH4. The crystal structure of this new hydride is tentatively indexed using an orthorhombic cell with a space group of Pna21 and lattice parameters of a = 9.643 Å, b = 6.228 Å, and c = 5.563 Å. The Li2NH-2LiBH4 sample shows excellent hydrogenation properties with hydrogen absorption starting at near-ambient temperature (50 °C), which is more than 100 °C lower than that of pristine Li2NH. Furthermore, it attains 100% hydrogenation under isothermal conditions at 60 °C and 50 bar hydrogen pressure. Such superior low-temperature hydrogen absorption may be due to the formation of this new complex hydride. Interestingly, above 97 °C, the lithium-ion conductivity of this new hydride is higher than those of Li2NH and LiBH4 and reaches 10-2 S cm-1 at 114 °C. Meanwhile, the ionic conductivity of this new hydride is â¼30 times higher than that of LiBH4 reaching 10-5 S cm-1 at room temperature. The interaction between imides and borohydrides described in this work expands the options for strategic design of novel hydrogen storage materials and solid ionic conductors.
RESUMO
A nitrogen-based complex hydride is investigated for hydrogen isotope separation for the first time. The experimental results show that a lithium amide-lithium hydride composite (Li-N-H) possesses a distinct positive isotope effect with a separation factor of 1.42. The H-D exchange process in this system occurs at 373 K and can be accelerated with the increase of temperature.
RESUMO
The disease caused by viral pneumonia called severe acute respiratory syndrome coronavirus type-2 (SARS-CoV-2) declared by the World Health Organization is a global pandemic that the world has witnessed since the last Ebola epidemic, SARS and MERS viruses. Many chemical compounds with antiviral activity are currently undergoing clinical investigation in order to find treatments for SARS-CoV-2 infected patients. On-going drug-drug interaction examinations on new, existing, and repurposed antiviral drugs are yet to provide adequate safety, toxicological, and effective monitoring protocols. This review presents an overview of direct and indirect antiviral drugs, antibiotics, and immune-stimulants used in the management of SARS-CoV-2. It also seeks to outline the recent development of drugs with anti-coronavirus effects; their mono and combination therapy in managing the disease vis-à-vis their biological sources and chemistry. Co-administration of these drugs and their interactions were discussed to provide significant insight into how adequate monitoring of patients towards effective health management could be achieved.
